MAP2K3 and colorectal carcinoma: In this study, we investigated whether a drug repurposing approach based on transcriptome data may identify FDA-approved drugs with inhibitory activity of the MKK3 signalling and thus mimicking the well-known biologic effects triggered by the inducible RNAi mediated silencing of MKK3 seen in CRC cells.